Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 9 pages · English
New York, USA: January 28 and Melbourne, Australia: January 29, 2026: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the second fiscal quarter ended December 31, 2025. “This quarter was highlighted by continued strong Ryoncil® sales and the establishment of a new lowercost no
Earlier from Mesoblast
- Ryoncil® Net Revenues Increase for the Quarter to US$30M
- Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
- FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
- Ryoncil Sales for the Quarter Increase 60% to US$35.1M
- Ryoncil® Sales Increase 60% in December Quarter to US$35.1M
Later from Mesoblast
- High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
- Ryoncil® Profits Underpinning Substantial Growth Pipeline
- Half Year Report and Accounts (including Appendix 4D)
- Corporate Presentation and Half Year Financial Results
- Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast